Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

12,000-Patient study tests new cholesterol pill in real life

NCT ID NCT07515560

Disease control Sponsor: Daewoong Pharmaceutical Co. LTD. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 12,000 Korean adults with dyslipidemia (high cholesterol) who are prescribed Baroezet Tablet by their doctor. Researchers will measure changes in LDL ("bad") cholesterol and other fats in the blood over 24 weeks, and track any side effects. The goal is to see how well the medication works in everyday medical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 12,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will enroll adult patients aged 19 years or older who are diagnosed with dyslipidemia in routine clinical practice in Korea. Eligible patients are those who require treatment with Baroezet Tablet 1/10 mg based on the physician's clinical judgment and provide written informed consent. Patients will be recruited from multiple centers across Korea in a real-world setting. Treatment decisions, including initiation and continuation of Baroezet Tablet, will be made according to routine clinical practice. Patients with contraindications to the study drug, including hypersensitivity to its components, active liver disease, or pregnancy, will be excluded.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥19 years * Patients diagnosed with dyslipidemia * Patients who require treatment with Baroezet Tablet * Patients who provide written informed consent Exclusion Criteria: * Hypersensitivity to study drug components * Active liver disease * Pregnant or breastfeeding women * Patients considered inappropriate by investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dyslipidemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dyslipidemias inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dyslipidemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Multiple centers in Republic of Korea

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.